Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (IMA901-202)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
immatics Biotechnologies GmbH
ClinicalTrials.gov Identifier:
NCT00523159
First received: August 30, 2007
Last updated: July 9, 2012
Last verified: February 2010

August 30, 2007
July 9, 2012
May 2007
August 2009   (final data collection date for primary outcome measure)
Disease control rate [ Time Frame: after 26 weeks ] [ Designated as safety issue: No ]
Disease control rate [ Time Frame: after 26 weeks ]
Complete list of historical versions of study NCT00523159 on ClinicalTrials.gov Archive Site
  • Tumor response rates and SD rate [ Time Frame: after 26 and 38 weeks ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: from the time response is first documented until the first date of recurrence or PD ] [ Designated as safety issue: No ]
  • Time to response [ Time Frame: From Visit c to PR or CR ] [ Designated as safety issue: No ]
  • TTP [ Time Frame: From visit C to until tumor progression ] [ Designated as safety issue: No ]
  • PFS and OS [ Time Frame: From visit C to tumor progression or death ] [ Designated as safety issue: No ]
  • DCR [ Time Frame: after 38 weeks on study ] [ Designated as safety issue: No ]
  • Immune response [ Time Frame: Visit C, 1, 5, 6, 7, 10 and 14 ] [ Designated as safety issue: No ]
  • Effect of cyclophosphamide pre-treatment on immune response [ Time Frame: Visit C, 1, 5,6,7, 10, 14 ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: From inclusion on the study until 3 weeks after end of study visit ] [ Designated as safety issue: Yes ]
  • Tumor response rates and SD rate [ Time Frame: after 26 and 38 weeks ]
  • - Duration of response
  • Time to response
  • TTP
  • PFS and OS
  • DCR [ Time Frame: after 38 weeks on study ]
  • Immune response
  • Effect of cyclophosphamide pre-treatment on immune response
  • Safety
Not Provided
Not Provided
 
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease

This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.

Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.

This is a multicenter, open label, randomized phase 2 study which investigated the effect of a second-line systemic treatment with IMA901 plus GM-CSF in RCC patients. Randomization was done according to a pre-treatment with low-dose cyclophosphamide (CY). Secondary endpoints comprised tumor response parameters.

The study population consisted of HLA-A*02-positive men or women with advanced RCC of the clear-cell type classified as having a favorable or intermediate risk after first-line systemic therapy for. Patients had to be aged 18 years or older, had at least have one measurable tumor lesion and had have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease, during or after which the patient had experienced disease progression.

Patients in both arms received a total of 17 vaccinations with GM-CSF followed by IMA901 during the 9 month treatment period.

At screening baseline tumor status was assessed by CT or MRI. During the study tumor assessments were performed every 6 weeks.

Immunomonitoring (T-cell responses to peptides contained in IMA901 and analysis of other immune cell populations that may influence T-cell responses), serum levels of antibodies and molecules with suspected influence on immune response were assessed on several occasions during the study.

Safety assessment comprised continuous adverse event reporting, regular physical examinations and regular assessments of vital signs, hematology, blood chemistry and urine. A 12-lead ECG was performed at screening and at the end of the study. Pregnancy testing was performed according to applicable legislation in the country where the trial was performed. At the very least, women of childbearing potential had have to undergo a pregnancy test during screening for the study, before the first dose was applied and at the end of the study.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Renal Cell Carcinoma
  • Drug: Endoxana, IMA901, Leukine
    a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
  • Drug: IMA901 and Leukine
    Intradermal injection of GM-CSF followed by intradermal injection of IMA901
  • 1
    Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
    Intervention: Drug: Endoxana, IMA901, Leukine
  • 2
    No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
    Intervention: Drug: IMA901 and Leukine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged at least 18 years
  • HLA type: HLA-A*02-positive
  • Histologically documented advanced clear-cell RCC
  • Patients who have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease systematic therapy for advanced disease and must be candidates for second-line therapy (NOTE: in Germany and Austria only patients after first-line tyrosine kinase inhibitor failure will be included into the study)
  • Patients having experienced documented tumor progression
  • At least one unidimensional measurable target lesion
  • Karnofsky Performance Status ≥ 80%
  • Favorable or intermediate risk according to the 3-score MSKCC criteria.
  • Able to understand the nature of the study and give written informed consent
  • Willingness and ability to comply with the study protocol for the duration of the study

Exclusion Criteria:

  • Poor risk according to the 3-score MSKCC criteria
  • Immunosuppressive therapy within 4 weeks before study entry, e.g. corticosteroid treatment
  • History of other malignant tumors, except non-melanoma-skin cancer or curatively excised cervical carcinoma in situ
  • Presence of brain metastases on MRI or CT scan
  • Patients with a history or evidence of systemic autoimmune disease
  • Any vaccination in the two weeks before study entry
  • Any planned prophylactic vaccination from study entry until the end of the induction period (5 weeks after the first vaccination)
  • Known active hepatitis B or C infection
  • Known HIV infection
  • Any other infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patient tissues.
  • Any of the following in the 4 weeks before study entry:

    1. Major surgery
    2. Anticancer treatments including (but not limited to) cytotoxic chemotherapy, radiotherapy, immunotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies
    3. Unresolved toxicity from prior anticancer treatments including (but not limited to) cytotoxic chemotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies, radiotherapy, or immunotherapy
    4. Received study drug within any clinical study
  • Any of the following abnormal laboratory values:

    1. Hematology: Hb < 9 g/dL; WBC < 3 x 109/L; neutrophils < 1.5 x 109/L; lymphocytes < 1.0 x 109/L; platelets < 100 x 109/L
    2. Liver function: serum bilirubin > 1.5 x upper normal limit (unless a history of Gilbert's disease); ALAT or ASAT > 3 x upper normal limit (>5 x upper normal limit if liver metastases are present)
    3. Renal function: serum creatinine > 200 µmol/L
  • Patients with other significant diseases currently uncontrolled by treatment which might interfere with study completion, for example:

    1. Heart failure or non compensated active heart disease
    2. Severe coronary heart disease, cardiac arrhythmia requiring medication, or uncontrolled hypertension
    3. Symptomatic neurotoxicity (motor or sensory) ≥ grade 2 National Cancer Institute - Common Toxicity Criteria (NCI-CTC).
    4. Severe pulmonary dysfunction
  • Psychiatric disabilities, seizures or central nervous system disorders that may interfere with the ability to give informed consent or perform adequate follow-up in the investigator's opinion
  • Active infections requiring oral or intravenous antibiotics
  • Women or men who decline to practice a medically approved method of contraception
  • Pregnancy or breastfeeding
  • Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Bulgaria,   Germany,   Hungary,   Poland,   Romania,   Slovakia,   Spain,   Switzerland,   United Kingdom
 
NCT00523159
EudraCT Nr: 2006-006370-25
Yes
immatics Biotechnologies GmbH
immatics Biotechnologies GmbH
Not Provided
Study Director: Alexandra Kirner, PhD immatics Biotechnologies GmbH
immatics Biotechnologies GmbH
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP